Automated Eye Disease Screening System

自动眼病筛查系统

• 批准号: 8250296
• 负责人: Peter N Soliz
• 金额: $ 60.54万
• 依托单位: VISIONQUEST BIOMEDICAL, LLC
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8250296
• 关键词: Address; Age; Age related macular degeneration; American; Automation; Blindness; Blood Vessels; Businesses; Caring; Centers for Disease Control and Prevention (U.S.); Clinical; Community Healthcare; Computer Assisted; Computer software; Computer-Assisted Diagnosis; Computers; Detection; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Disease; Early Diagnosis; Early treatment; Economics; Eye diseases; Fibrinogen; Frequencies; Glaucoma; Goals; Health Personnel; Health Services Accessibility; Healthcare Systems; Human; Hybrids; Hypertension; Image; Image Analysis; Individual; Institutes; Intervention; Joint Ventures; Lesion; Mammography; Manuals; Marketing; Measures; Medical; Medical Imaging; Methods; Microaneurysm; Modeling; New Mexico; Ocular Pathology; Ophthalmic examination and evaluation; Ophthalmologist; Optic Disk; Optometrist; Pallor; Pap smear; Pathology; Phase; Populations at Risk; Productivity; Quality of life; Reader; Reading; Reporting; Research; Research Infrastructure; Research Personnel; Retina; Retinal; Retinal Diseases; Risk; Risk Factors; Safety; Screening procedure; Sensitivity and Specificity; Services; Site; Solutions; South Texas; Specialist; Staging; System; Techniques; Technology; Testing; Texas; Time; Training; Universities; Vision; Work; advanced disease; age related; base; clinically significant; commercialization; cost; design; diabetic; image processing; improved; macular edema; meetings; neovascularization; patient safety; programs; proliferative diabetic retinopathy; research and development; success

DESCRIPTION (provided by applicant): This proposed project is motivated by the fact that comprehensive, broad-scale screening for eye diseases such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR), including advanced stages, is economically prohibitive without the introduction of computer-assisted diagnosis of retinal images. According to the CDC approximately 80 million people in the U.S. have some form of eye disease, including 20 million diabetics at risk for retinopathy, 60 million at risk for glaucoma, and 13 million diagnosed with AMD. It is estimated that less than half of those individuals with diabetes are screened periodically for DR. Lack of medical coverage and access to healthcare providers imposes major obstacles for nearly 10 million diabetics. Creating an affordable and accessible solution to providing screening services to these diabetics presents a significant challenge to the healthcare community. A comprehensive screening program for U.S. citizens utilizing ophthalmologists, optometrists, or other trained specialists, readers, to grade each case would be prohibitively expensive. The solution is to implement a computer-assisted technology similar to other medical applications, such as mammograms and Pap smears; that would provide comprehensive, periodic screening of our at-risk population. Our business models show a 400% decrease in costs with the integration of automation into today manual screening methods. The study will be made possible through the implementation of the infrastructure for a reading center in South Texas where it is estimated that nearly 200,000 diabetics reside and over 50% do not receive annual examinations. The center will be a demonstration site where the efficacy of the software can be documented for submission to the FDA for pre-market approval (PMA). The goal is to show that a center's through put number of cases screened per time period will increase fivefold through the use of a hybrid (automation-human graders) approach with sensitivity that is comparable or better than solely human-based screening. The significance of this proposed research is two-fold. First, by increasing the productivity of reading centers through automation, a much larger population of at-risk individuals will have access to this service, leading to improved productivity and quality of life through early detection and treatment. Second, by providing to the FDA, a system that is highly effective and sensitive to advanced disease, the issue of safety is essentially eliminated. PUBLIC HEALTH RELEVANCE: Today, the CDC reports that there are about 80 million people in the US who have some form of eye disease. Diabetic retinopathy, age-related macular degeneration, and glaucoma are the leading causes of blindness. There is some form of intervention for each of these eye diseases that can result in the extension of useful vision, if detected early. Our automated eye disease screening system will make examination available to millions of Americans at risk for eye disease available without major impact on our healthcare system. This is possible only through automation as an adjunct to examinations by eye care specialists.

描述（由申请人提供）：该提议的项目是由以下事实激发的：诸如与年龄相关的黄斑变性（AMD），青光眼和糖尿病性视网膜病变（包括高级阶段）等全面的，诸如与年龄有关的黄斑变性（AMD）等眼睛疾病的事实是经济上的刺激性，而无需引入计算机认可的视网膜图像诊断。根据美国疾病预防控制中心（CDC）的说法，美国约有8000万人患有某种形式的眼科疾病，其中包括有2000万个糖尿病患者患视网膜病的风险，有6000万人患有青光眼的风险和1300万诊断为AMD的糖尿病患者。据估计，对于DR的糖尿病患者中，只有不到一半的糖尿病患者进行筛查。缺乏医疗保险和获得医疗保健提供者的机会，对近1000万个糖尿病患者施加了主要障碍。为这些糖尿病患者提供筛查服务的负担得起且易于使用的解决方案给医疗保健社区带来了重大挑战。使用眼科医生，验光师或其他训练有素的专家，读者对每种情况进行评分的全面筛查计划将非常昂贵。解决方案是实施类似于其他医学应用的计算机辅助技术，例如乳房X线照片和子宫颈抹片检查；这将为我们的高危人口提供全面的周期性筛查。我们的业务模型显示，随着自动化的整合到当今的手动筛选方法中，成本下降了400％。这项研究将通过在南德克萨斯州的阅读中心实施基础设施来实现，据估计，据估计，将近20万糖尿病患者居住，超过50％的人未接受年度考试。该中心将是一个示范站点，可以将软件的功效记录在FDA中以进行前市场批准（PMA）。目的是表明，通过使用混合动力车（自动化 - 人类毕业生）方法，具有可比性或比仅仅基于人类的筛选更好的敏感性，通过使用混合动力车（自动化 - 人类毕业生）方法将增加五倍的情况。这项拟议的研究的意义是两倍。首先，通过通过自动化提高阅读中心的生产率，高危人群将可以使用这项服务，从而通过早期检测和治疗提高生产率和生活质量。其次，通过向FDA提供对晚期疾病非常有效且敏感的系统，可以实质上消除了安全问题。 公共卫生相关性：今天，疾病预防控制中心（CDC）报告说，美国大约有8000万人患有某种形式的眼科疾病。糖尿病性视网膜病，与年龄相关的黄斑变性和青光眼是失明的主要原因。对于每种眼部疾病，都有某种形式的干预，如果早期检测到，可能会导致有用视力的扩展。我们的自动眼病筛查系统将使数百万有眼科疾病的美国人可以接受检查，而不会对我们的医疗保健系统产生重大影响。这只有通过自动化作为眼保健专家进行检查的辅助功能才有可能。